论文部分内容阅读
目的探讨奥扎格雷治疗急性脑梗死(ACI)的临床疗效。方法将140例ACI患者随机分为两组,每组70例。两组常规治疗相同,在此基础上,治疗组给予奥扎格雷注射液160mg加入生理盐水250ml静脉滴注,1次/d;对照组给予复方丹参20ml加入生理盐水250ml中静脉滴注,1次/d。治疗14d后观察患者凝血酶原时间、纤维蛋白原、高密度脂蛋白、三酰甘油等生化指标以及评价其疗效。结果治疗组总有效率明显高于对照组(P<0.01),治疗组纤维蛋白原、高密度脂蛋白、三酰甘油、凝血酶原时间比治疗前明显改善(P<0.01)。结论早期使用奥扎格雷治疗ACI安全有效,值得推广。
Objective To investigate the clinical efficacy of ozagrel in the treatment of acute cerebral infarction (ACI). Methods 140 patients with ACI were randomly divided into two groups of 70 cases. Two groups of conventional treatment the same, on this basis, the treatment group given Ozagrel injection 160mg intravenous infusion of normal saline 250ml, 1 / d; control group given compound Salvia 20ml added saline 250ml intravenous infusion, once / d. After 14 days of treatment, prothrombin time, fibrinogen, high density lipoprotein, triglyceride and other biochemical indexes were observed and evaluated. Results The total effective rate of the treatment group was significantly higher than that of the control group (P <0.01). The fibrinogen, high density lipoprotein, triglyceride and prothrombin time of the treatment group were significantly improved (P <0.01). Conclusion Early use of ozagrel in the treatment of ACI is safe and effective, which is worth promoting.